Skip to main content

ADC Therapeutics SA

ADCT
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001771910

No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding ADC Therapeutics SA changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of ADCT: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders6059−1
Shares38.8M46.6M+7.78M (+20.0%)
Value$149.1M$90.9M−$58.2M (−39.0%)

New holders (17)

Institutions that held ADC Therapeutics SA at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to ADCT in Q1 2023
InstitutionSharesValue% of portfolio
Sio Capital Management, LLC2,160,632$4.21M2.08%
Frazier Life Sciences Management, L.P.1,647,030$3.21M0.23%
Perceptive Advisors LLC1,495,805$2.92M0.09%
Affinity Asset Advisors, LLC600,000$1.17M0.45%
Barclays PLC334,272$651.8K0.00%
Marshall Wace, LLP157,679$307.5K0.00%
Woodline Partners LP143,403$279.6K0.00%
Fred Alger Management, LLC125,985$245.7K0.00%
Squarepoint Ops LLC104,547$203.9K0.00%
Qube Research & Technologies Ltd77,166$150.5K0.00%
Jane Street Group, LLC25,584$49.9K0.00%
Gsa Capital Partners LLP23,648$46.0K0.00%
HRT Financial LP16,334$31.0K0.00%
Dynamic Technology Lab Private Ltd14,332$28.0K0.00%
Prospera Financial Services Inc12,623$24.6K0.00%
Verition Fund Management LLC11,241$21.9K0.00%
Commonwealth Equity Services, LLC10,093$19.0K0.00%

Sold out (18)

Institutions that held ADC Therapeutics SA at the end of Q4 2022 and filed for Q1 2023 without it.